Biotechnology exchange traded funds can hold a hodgepodge of businesses with approved drugs and those focused on clinical trials. So ETF sponsor BioShares puts these companies into two distinct funds. Biotechnology Clinical Trials (BBC) and Biotechnology Products (BBP) launched in December 2014. The ETFs started with a little over $5 million combined. They now together hold roughly $58 million.